Open AccessSingle‐Agent Versus Double‐Agent Chemotherapy in Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma: Prospective, Randomized, Multicenter Phase II Clinical Trial
Author(s) -
Zhao Zhenhuan,
Wen Yixue,
Liao Dongbiao,
Miao Jidong,
Gui Yan,
Cai Hongwei,
Chen Yang,
Wei Min,
Jia Qiang,
Tian Honggang,
Sun Mingqiang,
Zhang Yu,
Feng Gang,
Du Xiaobo
Publication year - 2020
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2020-0808
Subject(s) - medicine , chemoradiotherapy , chemotherapy , oncology , radiation therapy , cisplatin , randomized controlled trial , phases of clinical research , survival rate , gastroenterology
Lessons Learned The efficacy of single‐agent chemotherapy was not significantly different from that of double‐agent chemotherapy in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma. Single‐agent concurrent chemoradiotherapy had lower gastrointestinal and hematologic toxicity. Overall survival and progression‐free survival were not significantly different between single‐ and double‐agent concurrent chemoradiotherapy.Background This multicenter, randomized, phase II trial aimed to compare the efficacy and safety of single‐agent concurrent chemoradiotherapy using the oral fluoropyrimidine S‐1 with those of double‐agent concurrent chemoradiotherapy using S‐1 and cisplatin in patients with inoperable esophageal squamous cell carcinoma. Methods Patients with inoperable esophageal squamous cell carcinoma (clinical stages I to III) were randomly allocated to the single‐agent group (S‐1) or the double‐agent group (S‐1/cisplatin). The concurrent intensity‐modulated radiation therapy plan was similar for both groups: planning target volume 1.8 Gy/f*30–33f and planning gross target volume of 2 Gy/f*30–33f. The primary outcome measure was the endoscopic complete response rate. Results Of the 105 patients randomized, 89 were assessable. The endoscopic complete response rate was 46.9% (23/49) in the single‐agent group and 52.5% (21/40) in double‐agent group. The median progression‐free survival within a median follow‐up of 23 months was 20 and 21 months, respectively. The median overall survival was 26 months and not reached, respectively. Grade 3 hematological toxicities occurred in 4.1% and 27.5% of the patients in the single‐ and the double‐agent group, respectively. Conclusion Single‐agent chemotherapy in concurrent chemoradiotherapy for inoperable esophageal squamous cell carcinoma has good efficacy and safety, thus warranting a phase III trial.